32P Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Authors :: S. Ali
M. Watras
Robin Katie Kelley
Brian Evans
Alejandra Negro
Ghassan K. Abou-Alfa
Nathan Standifer
C. Chen
Source :: Annals of Oncology. 31:S1429
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Durvalumab
business.industry
Immunogenicity
Hematology
medicine.disease
Regimen
Hepatocellular carcinoma
Internal medicine
medicine
In patient
business
Tremelimumab
medicine.drug

Full Text Access

Tools